Introduction {#Sec1}
============

Osteoporotic fractures place a large burden on patients and a major economic toll on society \[[@CR1]\]. Fractures of the distal radius are the most common upper extremity fracture in older adults, comprising approximately 22% of all fractures in women aged 50 and above, with an annual incidence of 8--10 per 1000 person-years, similar to the rate of hip fractures (7 per 1000 person-years) \[[@CR2], [@CR3]\]. At age 50 years, a white woman's lifetime risk of a wrist fracture is 16% \[[@CR4]\]. In the Study of Osteoporotic Fractures, elderly women with wrist fractures were almost 50% more likely to have a clinically important functional decline than those without fractures \[[@CR3]\]. Mortality in elderly patients with distal radius fractures is significantly higher than a matched cohort of the general population without fracture \[[@CR5]\].

Wrist fractures are also associated with an increased subsequent risk of vertebral and hip fractures \[[@CR6]--[@CR8]\]. An analysis of the National Osteoporosis Risk Assessment (NORA) study of 158,940 postmenopausal women showed a threefold risk of subsequent wrist fracture, and a twofold risk of any osteoporotic fracture, in women with prior wrist fracture, after adjusting for multiple covariates \[[@CR6]\]. An analysis of the Women's Health Initiative Observational Study and Clinical Trials showed that, after a mean duration of follow-up of 11.8 years, 15.5% of women who experienced wrist fracture subsequently experienced a non-wrist fracture, with a hazard ratio (HR) of 1.40 (95% confidence interval (CI) 1.33--1.48) compared with women without prior wrist fracture, after adjusting for age, race, and BMI \[[@CR7]\].

Most wrist fractures involve the ultradistal radius, a zone with a high proportion of trabecular bone \[[@CR9]\]. The 1/3 radius site is predominantly denser cortical bone (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR10]\]. Although the 1/3 radius is the forearm site most commonly considered with dual-energy x-ray absorptiometry (DXA) measurements \[[@CR11]\], use of areal bone mineral density (BMD) at the ultradistal radius has recently been shown to improve fracture risk estimation compared with BMD at the femoral neck alone \[[@CR12]\].Fig. 1Composition of the distal radius and regions of interest in dual X-ray absorptiometry measurements

Abaloparatide selectively binds to the RG versus R^0^ conformation of the parathyroid hormone type 1 receptor (PTHR1), resulting in transient receptor signaling consistent with a net anabolic effect \[[@CR13], [@CR14]\]. Preclinical studies demonstrated increases in BMD, restoration of bone microarchitecture, and increased bone strength \[[@CR15]--[@CR17]\]. In a 24-week phase II clinical trial in postmenopausal women with osteoporosis, abaloparatide demonstrated dose-dependent increases in BMD at the lumbar spine, femoral neck, and total hip compared with placebo \[[@CR14]\], and improvements in skeletal microarchitecture of the lumbar spine, assessed indirectly by trabecular bone score \[[@CR18]\]. In the 18-month phase 3 Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE), postmenopausal women with osteoporosis were randomized to receive double-blind abaloparatide or placebo or open-label teriparatide. In ACTIVE, abaloparatide decreased the risk of vertebral and nonvertebral fractures compared with placebo and decreased the risk of major osteoporotic fractures compared with teriparatide \[[@CR19]\].

The objectives of this exploratory analysis of ACTIVE were to determine the effect of abaloparatide on BMD at an anatomical site with a high proportion of trabecular bone relevant to wrist fractures (the ultradistal radius), as well as at a site with a higher proportion of cortical bone (the 1/3 radius), and to assess the effect on wrist fracture incidence.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

The multicenter, multinational, randomized controlled ACTIVE study ([clinicaltrials.gov](http://clinicaltrials.gov) identifier: NCT01343004) enrolled 2463 postmenopausal women, ages 49 to 86 years, with osteoporosis as defined by prior radiographic vertebral fracture or recent (within 5 years of enrollment) nonvertebral fracture with a BMD T-score ≤ −2.5 at the lumbar spine or femoral neck if age ≤ 65 years or ≤ −2.0 if age \> 65 years. For those aged \> 65 years, no prior fracture was required if the lumbar spine or femoral neck BMD T-score was ≤ −3.0. Other inclusion/exclusion criteria have been previously described \[[@CR19]\].

Study design {#Sec4}
------------

The protocol was approved by the respective institutional review boards. After informed written consent was obtained, women were screened and those eligible were randomized 1:1:1 to receive double-blinded daily subcutaneous injections of abaloparatide 80 μg or matching placebo, or open-label daily injections of teriparatide 20 μg for 18 months \[[@CR19]\]. All women received supplements of 500 to 1000 mg/day calcium and 400 to 800 IU vitamin D based on regional standard of care. The study was conducted in accordance with the ethical principles contained in the declaration of Helsinki and in compliance with good clinical practice guidelines and all applicable local regulations and ethical requirements.

Endpoints {#Sec5}
---------

The primary endpoint of ACTIVE was the incidence of new vertebral fractures from baseline to 18 months in women treated with abaloparatide compared with placebo \[[@CR19]\]. Between-group comparisons of changes in BMD from baseline at the ultradistal and 1/3 radius, and the incidence of wrist fractures, were prespecified exploratory efficacy endpoints for abaloparatide versus placebo and abaloparatide versus teriparatide. All comparisons between teriparatide and placebo, and BMD changes from baseline within treatment groups, were post hoc exploratory analyses. Changes in BMD from baseline were assessed at the ultradistal and 1/3 radius at 6, 12, and 18 months in a subset of women who had at least one baseline and post-baseline measurement. BMD was measured by Lunar (GE Healthcare; Madison, WI, USA) or Hologic (Hologic, Inc.; Marlborough, MA, USA) dual energy X-ray absorptiometry (DXA) and centrally analyzed (Bioclinica-Synarc, Newark, CA, USA) using the percentage change from baseline in BMD, adjusted for machine differences. Clinical wrist fractures were ascertained from the total ACTIVE intent-to-treat population of 2463 randomized women, initially self-reported and then verified from source documents. All wrist fractures that caused a patient to seek medical care, regardless of the level of trauma, were included.

Study oversight was performed and safety was assessed as previously described \[[@CR19]\], and all assessors of BMD and fracture were blinded to treatment group assignments.

Statistical analyses {#Sec6}
--------------------

Percent changes in BMD from baseline were evaluated at each study visit, with missing data imputed based on last observation carried forward. Comparisons within treatment groups were performed using *t* test. Comparisons among treatment groups were performed using analysis of covariance (ANCOVA) models. DXA scanner (Lunar or Hologic) and baseline BMD were included as covariates in ANCOVA models. Kaplan-Meier curves were used to display cumulative wrist fracture incidence. Time to first wrist fracture was compared using the log-rank test; hazard ratios (HR) were calculated using the Cox proportional hazards model. Similar analyses were conducted for analyses of wrist fracture by prior wrist fracture status. *p* values were not adjusted for multiple comparisons and were considered significant for *p* \< 0.05.

Results {#Sec7}
=======

Subject disposition and demographics {#Sec8}
------------------------------------

The subject disposition and demographic characteristics in ACTIVE have been previously described \[[@CR19]\]. BMD measurements at the ultradistal radius and the 1/3 radius were performed in a subset of 982 women representing 14 study sites randomized to receive abaloparatide (*n* = 321), placebo (*n* = 334), or teriparatide (*n* = 327). Baseline characteristics of this subset (Table [1](#Tab1){ref-type="table"}) were similar to the full cohort with mean age 68.4 years, mean femoral neck T-score − 2.2, 24.6% having prevalent vertebral fracture and 32.7% reporting prior nonvertebral fracture within the past 5 years. Approximately 22% of the subset reported any prior history of wrist fracture.Table 1Demographics and baseline characteristics of the ACTIVE overall population and women with wrist BMD measurementsCharacteristicPlaceboAbaloparatideTeriparatideOverall, *n* = 821Wrist, *n* = 334Overall, *n* = 824Wrist, *n* = 321Overall, *n* = 818Wrist *N* = 327Age, years, mean (SD)68.7 (6.5)68.1 (6.6)68.9 (6.5)68.7 (6.2)68.8 (6.6)68.2 (6.2)BMI, kg/m^2^, mean (SD)25.1 (3.6)24.4 (3.5)25.0 (3.5)24.5 (3.6)25.2 (3.6)24.6 (3.7)Race, *n* (%) White655 (79.8)234 (70.1)663 (80.5)221 (68.8)645 (78.9)221 (67.6) Asian131 (16.0)98 (29.3)128 (15.5)99 (30.8)137 (16.7)104 (31.8) Black or African-American23 (2.8)2 (0.6)26 (3.2)024 (2.9)1 (0.3) Other12 (1.5)07 (0.8)1 (0.3)12 (1.5)1 (0.3)Hispanic or Latino, *n* (%)199 (24.2)12 (3.6)199 (24.2)11 (3.4)194 (23.7)11 (3.4)BMD T-score, mean (SD) Total hip−1.9 (0.8)−2.0 (0.8)−1.9 (0.7)−1.9 (0.7)−1.9 (0.8)−1.9 (0.7) Femoral neck−2.2 (0.7)−2.2 (0.7)−2.2 (0.6)−2.2 (0.6)−2.1 (0.7)−2.2 (0.7) Lumbar spine−2.9 (0.8)−2.9 (0.9)−2.9 (0.9)−2.8 (0.8)−2.9 (0.9)−2.9 (0.9) Ultradistal radius--−3.3 (1.3)--−3.3 (1.3)--−3.3 (1.3) 1/3 radius--−2.8 (1.2)--−2.8 (1.1)--−2.8 (1.1)Prevalent vertebral fracture at baseline, *n* (%)188 (22.9)82 (24.6)177 (21.5)71 (22.1)220 (26.9)88 (26.9)Prior nonvertebral fracture within last 5 years, *n* (%)266 (32.4)118 (35.3)248 (30.1)96 (29.9)240 (29.3)107 (32.7)Prior wrist fracture, *n* (%)\*173 (21.1)75 (22.5)178 (21.6)69 (21.5)158 (19.3)69 (21.1)No history of prior fracture, *n* (%)\*307 (37.4)114 (34.1)305 (37.0)116 (36.1)308 (37.7)121 (37.0)\*Lifetime historyBMD, bone mineral density; BMI, body mass index. Values for overall population are from Miller et al. \[[@CR19]\]

Changes in BMD {#Sec9}
--------------

### BMD change from baseline: between-group differences {#Sec10}

Between-group comparisons of BMD percent changes from baseline were prespecified exploratory analyses.

Increases from baseline in BMD at the ultradistal radius at 6 months were significantly greater for the abaloparatide group compared with placebo and remained higher for the duration of study (Fig. [2](#Fig2){ref-type="fig"}a). By 18 months, BMD change from baseline at the ultradistal site was 2.25 percentage points greater for the abaloparatide group compared with placebo and 1.54 percentage points greater for abaloparatide compared with teriparatide (Suppl Table [1](#MOESM1){ref-type="media"}). Ultradistal BMD change from baseline at 18 months was not significantly different for teriparatide compared with placebo.Fig. 2Mean percent changes in bone mineral density (BMD) at (**a**) the ultradistal radius and (**b**) the 1/3 radius. Missing BMD data were imputed using the method of last observation carried forward. Errors bars in icate 95% confidence intervals. \**p* \< 0.001 vs placebo; @*p* \< 0.01 vs placebo; †*p* \< 0.001 vs teriparatide; \#*p* \< 0.01 vs teriparatide; ‡*p* \< 0.001 vs baseline; §*p* \< 0.01 vs baseline; ¶*p* \< 0.05 vs baseline

BMD decreases at the 1/3 radius were comparable between placebo and abaloparatide, but greater for teriparatide compared with placebo, at each time point (Fig. [2](#Fig2){ref-type="fig"}b). At 18 months, 1/3 radius BMD decreased 0.42% compared with placebo (*p* = 0.19, not significant) but the decline with abaloparatide was significantly lower than that seen with teriparatide (difference 1.22 percentage points, *p* \< 0.001, Suppl Table [2](#MOESM1){ref-type="media"}). BMD losses at the 1/3 radius at 18 months were also greater for teriparatide compared with placebo (difference 1.66 percentage points, *p*\< 0.001).

Within-group BMD change from baseline {#Sec11}
-------------------------------------

BMD at the ultradistal radius increased above baseline at 6 months for the abaloparatide and teriparatide groups (Fig. [2a](#Fig2){ref-type="fig"}). Mean percent change from baseline at the ultradistal radius at 6 months was 1.62% for the abaloparatide group and 0.74% for the teriparatide group (Suppl Table [1](#MOESM1){ref-type="media"}). In the placebo group at 6 months, mean percent change from baseline at the ultradistal radius was 0.05%. By 18 months, mean percent change was 1.04% above baseline for abaloparatide but was similar to baseline at 18 months for teriparatide (Suppl Table [1](#MOESM1){ref-type="media"}). In the placebo group at 18 months, ultradistal BMD had declined below baseline.

At the 1/3 radius, mean BMD at 6 months was similar to baseline for abaloparatide and placebo but decreased from baseline for teriparatide. The mean percent change from baseline at 6 months was −0.01% in the abaloparatide group, − 0.15% in the placebo group and − 0.93% in the teriparatide group (Suppl Table [2](#MOESM1){ref-type="media"}). By 18 months, BMD at the 1/3 radius decreased compared with baseline within each treatment group (Fig. [2](#Fig2){ref-type="fig"}b). The mean percent change from baseline was − 1.02% in the abaloparatide group, − 0.62% in the placebo group, and − 2.27% in the teriparatide group (Suppl Table [2](#MOESM1){ref-type="media"}).

Wrist fractures {#Sec12}
---------------

In the total cohort, there were 7 women with incident wrist fractures in the abaloparatide group (Kaplan-Meier estimate, 1.0%), 15 in the placebo group (2.2%), and 17 in the teriparatide group (2.3%; Fig. [3](#Fig3){ref-type="fig"}). All were minimal trauma fragility fractures except 2 in the placebo group that were assessed as due to trauma. There was a numerically, although not statistically significant, lower incidence of wrist fracture with abaloparatide compared with teriparatide (HR = 0.43, 95% CI 0.18, 1.03, *p* = 0.052) and abaloparatide compared with placebo (HR = 0.49, 95% CI 0.20, 1.19, *p* = 0.11). A similar trend was observed among the subgroup of women with wrist BMD measurements (abaloparatide 2.1%; placebo 3.4%; teriparatide 2.9%), although differences were not statistically significant (Suppl Fig. [1](#MOESM1){ref-type="media"}). In the full ACTIVE cohort, there were 509 women who had a history of prior wrist fracture. After 18 months of treatment, the incidence of new wrist fractures was numerically higher for women with versus without prior wrist fracture (Fig. [3](#Fig3){ref-type="fig"}). Of those women with a prior wrist fracture, there was 1 woman with a new wrist fracture in the abaloparatide group (Kaplan-Meier estimate, 0.6%), 5 in the placebo group (3.2%), and 5 in the teriparatide group (3.4%). The Kaplan-Meier curve for time to first wrist fracture suggests an early separation between abaloparatide and teriparatide and a longer-term separation between abaloparatide and placebo; however, results should be interpreted with caution since numbers of wrist fractures at these time points were small (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Wrist fractures following 18 months of treatment, by prior history of wrist fracture. The percent of wrist fractures was calculated using cumulative Kaplan-Meier estimates at 19 months. CI, confidence interval; HR, hazard ratioFig. 4Kaplan-Meier curve for time to first wrist fracture. CI, confidence interval; HR, hazard ratio

Discussion {#Sec13}
==========

These analyses from the ACTIVE trial demonstrate that abaloparatide increased BMD at the predominantly trabecular ultradistal radius site more than teriparatide at the early time point (6 months) and the increase with abaloparatide was sustained over 18 months. These results are consistent with greater early increases in lumbar spine BMD observed with abaloparatide compared with teriparatide in the ACTIVE trial \[[@CR19]\]. BMD at the cortical 1/3 radius site declined similarly for abaloparatide and placebo but decreased significantly more with teriparatide. We hypothesize that this is due to differences in stimulation of cortical remodeling for the two treatments. Several studies of teriparatide have shown evidence of increased cortical porosity in animal models \[[@CR21], [@CR22]\] and clinical studies \[[@CR23], [@CR24]\]. Although confirmation with clinical studies is required, abaloparatide has not shown evidence of cortical porosity in rodent or primate animal models \[[@CR16], [@CR17]\].

Consistent with the BMD findings, over 19 months, there were fewer wrist fractures with abaloparatide compared with both teriparatide and placebo. The Kaplan-Meier curve for time to first wrist fracture suggests an early separation between abaloparatide and teriparatide, consistent with a greater initial anabolic effect of abaloparatide, as well as perhaps a lesser increase in bone remodeling with abaloparatide. However, these results should be interpreted with caution since numbers of wrist fractures at these time points were small. The lower incidence of wrist fractures seen with abaloparatide (in both women with and without a prior history of wrist fracture) is similar to results observed for nonvertebral, clinical, and major osteoporotic fractures in the ACTIVE study \[[@CR19]\].

The combination of BMD changes at the ultradistal radius and lower number of wrist fractures is noteworthy. The 2015 Official Positions of the International Society for Clinical Densitometry (ISCD) recommended against use of any forearm region except the 1/3 radius for diagnosis of osteoporosis \[[@CR11]\]. While both the geometric properties of the cortical shell and the mineral densities of trabecular bone have been shown to be of value in predicting fracture risk, BMD at the ultradistal site is an independent predictor of the load needed to cause a fracture \[[@CR25]\]. The occurrence of Colles' fracture is correlated with BMD decrease at the ultradistal radius \[[@CR26]--[@CR28]\], and habitual loading at the ultradistal radius is correlated with improved BMD and bone mineral content (BMC) \[[@CR20]\]. More recently, BMD at the ultradistal radius and the femoral neck was shown to improve prediction of hip fractures compared with femoral neck BMD alone, likely due to the combined trabecular and cortical bone parameters \[[@CR12]\]. The results of the current analyses are consistent with these observations and suggest a potential role for ultradistal radius BMD assessment in predicting forearm fracture risk.

Teriparatide is effective in reducing vertebral and nonvertebral fractures. Furthermore, there were numerically fewer wrist fractures with teriparatide compared with placebo in the teriparatide registration trial \[[@CR29]\]. Some studies predicted that teriparatide treatment increased mechanical strength at the distal radius using geometric parameters \[[@CR30]\] and others showed no change in bone strength using finite element analysis \[[@CR24], [@CR31], [@CR32]\]. Zanchetta et al. compared parameters of cortical bone quality at the predominantly cortical 15% (mid-distal) radius site using peripheral quantitative computed tomography (pQCT) cross-sectionally after 18 months of placebo, teriparatide 20 μg, or teriparatide 40 μg daily in 38 patients. There were no differences in cortical BMD or cortical thickness among treatment groups \[[@CR30]\]. Several groups used high resolution pQCT at the distal radius over 12 to 24 months in small studies of 11 to 30 women receiving teriparatide. The findings from these studies were inconsistent, with one showing a significant decrease in total BMD and trabecular thickness and trends for decreased trabecular bone volume ratio and cortical BMD \[[@CR24]\], one showing decreased cortical density and increased cortical porosity (but increased cortical thickness) \[[@CR31]\], and one showing decreased cortical BMD and increased cortical porosity \[[@CR32]\].

Although conclusions may be limited regarding the effects of teriparatide on these compartments of the wrist, given the small sample size of the studies, the ACTIVE study allows a direct comparison of teriparatide to abaloparatide in a large population of women with postmenopausal osteoporosis \[[@CR19]\]. The differences between these two drugs may relate to differential PTH1 receptor binding of abaloparatide compared with teriparatide, allowing for a higher dose of abaloparatide (80 mcg/d) compared with teriparatide (20 mcg/d) and leading to greater stimulation of bone formation and less stimulation of bone resorption \[[@CR13]\]. The different effects of these two agents on BMD at the ultradistal radius and 1/3 radius, and on wrist fracture, may relate to increased trabecular BMD and less intracortical bone resorption with abaloparatide compared with teriparatide. Several studies have observed an increase in cortical porosity with teriparatide treatment related to an increase in remodeling \[[@CR21], [@CR30], [@CR33]\]. Given the exploratory nature of the current analyses, confirmation of these hypotheses awaits future studies directly comparing the effects of abaloparatide and teriparatide on compartments of trabecular and cortical bone.

There are limitations to these analyses. It is important to note that DXA measurement can be especially challenging at the ultradistal site because bone density changes substantially along the length of the forearm \[[@CR34]\]. All analyses are exploratory, and results are therefore hypothesis-generating rather than confirmatory. Teriparatide was administered in an open-label format during ACTIVE, because it could be administered only via its trademarked injection pen. Wrist fracture incidence was low in all treatment arms, and although there were numerical differences, these were not statistically significant. There was a substantially higher proportion of Asian women in the study compared with other ethnicities. Furthermore, there was a patient dropout rate of approximately 25%; and the low incidence of wrist fractures and lack of forearm BMD in the full cohort precludes any assessment of the relationship between BMD changes and fracture risk in this study.

In conclusion, treatment with abaloparatide resulted in greater BMD increases at the more trabecular ultradistal radius compared with both the placebo and teriparatide groups and ultradistal radius BMD was better maintained with abaloparatide compared with teriparatide at the more cortical 1/3 site. These data are consistent with the numerically lower incidence of wrist fracture observed in women treated with abaloparatide compared with both teriparatide and placebo.
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